Table 1 Patient characteristics and correlation of clinicopathological parameters to CD36 status.
n = 109 | CD36 negative (n = 73) | CD36 positive (n = 36) | P value | OR [95% CI] | ||
|---|---|---|---|---|---|---|
Histology | HGSOC | 109 (100%) | 73 | 36 | ||
age | < 65 | 71 (65.1%) | 48 | 23 | 1.000 | 1.09 [0.43–2.69] |
≥ 65 | 38 (34.9%) | 25 | 13 | |||
FIGO stage | III | 77 (70.6%) | 49 | 28 | 0.274 | 0.59 [0.20–1.58] |
IV | 32 (29.4%) | 24 | 8 | |||
Residual tumor | R0 | 61 (56.0%) | 46 | 15 | 0.042 | 2.37 [0.98–5.86] |
R1 | 48 (44.0%) | 27 | 21 | |||
Bevacizumab | Yes | 70 (64.2%) | 43 | 27 | 0.137 | 2.08 [0.80–5.77] |
No | 39 (35.8%) | 30 | 9 |
